Status:
COMPLETED
Entacapone Augmentation for Schizophrenia
Lead Sponsor:
Rambam Health Care Campus
Conditions:
Schizophrenia
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
This study is testing the hypothesis that Entacapone added to ongoing antipsychotic treatment can be beneficial in schizophrenic patients with negative symptoms.
Eligibility Criteria
Inclusion
- predominantly negative symptoms
- stable on ongoing antipsychotic treatment
Exclusion
- acute psychotic exacerbation
- suicidal ideation
- uncontrolled systemic disease
Key Trial Info
Start Date :
June 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2006
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT00192855
Start Date
June 1 2003
End Date
October 1 2006
Last Update
August 25 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rambam medical center
Haifa, Israel, 31096